35.0065  -0.069 (-0.2%)		02-20 16:00
Open: 34.74 High: 35.08 Volume: 3,916		Pre. Close: 35.0759 Low: 34.74 Market Cap: 28(M)

Short term
Mid term
Targets	6-month :	41.37	1-year :	48.32
Resists	First :	35.42	Second :	41.37
Pivot price	34.82
Supports	First :	33.73	Second :	32.7
MAs	MA(5) :	35.13	MA(20) :	34.58
	MA(100) :	32.04	MA(250) :	28.56
MACD	MACD :	0.4	Signal :	0.4
%K %D	K(14,3) :	81.9	D(3) :	85.2
RSI	RSI(14): 60.1
52-week	High :	35.42	Low :	22.99

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ FTXH ] has closed below upper band by 38.5%. Bollinger Bands are 15.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	35.15 - 35.37	35.37 - 35.52
Low:	34.23 - 34.51	34.51 - 34.72
Close:	34.63 - 35.05	35.05 - 35.36

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.

Fri, 16 Jan 2026
Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks' - Benzinga

Sat, 15 Nov 2025
Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs - Benzinga

Fri, 14 Nov 2025
Pharma ETFs in Spotlight Following Robust Q3 Earnings Results - Zacks Investment Research

Wed, 12 Nov 2025
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' - Benzinga

Thu, 16 Oct 2025
ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook - TradingView

Fri, 26 Sep 2025
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit - The Globe and Mail

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Financial Services
Industry: Asset Management
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.